Silo Pharma, Inc. (NASDAQ: SILO) announced that its board of directors approved a share repurchase program to acquire up to $1 million of the company’s common stock. The program allows the company to buy shares on the open market, through privately negotiated transactions, or other methods that comply with U.S. Securities and Exchange Commission rules.
The announcement corrects a prior reporting error: the company’s May 2025 public offering was priced at approximately $2 million, not $1.59 million, and no $500,000 warrant exercise was reported. The program is not a commitment to purchase a specific number of shares; the timing, volume, and price will depend on market conditions and regulatory constraints.
Silo’s share repurchase comes amid several liquidity‑related developments. The company received a Nasdaq extension to regain compliance with the $1.00 bid‑price requirement, with a deadline of June 22 2026. On February 20 2026, the company issued $250,000 of stock to its investor‑relations consultant as a commitment fee, preserving cash for research and development. In the quarter ended September 30 2025, Silo reported a net loss of $1.20 million, or $0.19 per share, compared with a $0.95 million loss, or $0.31 per share, in the prior year, and its shares outstanding were 13,318,273 as of November 13 2025.
Management stated that the current capital‑market conditions allow the company to capture additional value for shareholders through this measured buyback program. The program is intended to support the stock price while maintaining liquidity for ongoing R&D initiatives, particularly the development of SPC‑15 for PTSD and other CNS indications. The buyback signals confidence in the company’s valuation and a commitment to shareholder value.
The announcement was met with a strong market reaction, reflecting investor confidence in the buyback program and the Nasdaq compliance extension.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.